Telavancin

Vancomycin MICs were determined by broth microdilution using cation-adjusted Mueller–Hinton Broth (CA-MHB, Bio-Rad, Marnes-la-Coquette, France) according to ISO 20776-1-2010. For daptomycin testing, CA-MHB was supplemented with Ca²⁺ (with a final concentration of 50 mg/L). The results were interpreted according to recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST v. 12.0). Vancomycin and daptomycin were purchased from Molekula (Darlington, UK), and lypoglycopeptides (oritavancin, dalbavancin, and telavancin) were purchased from Biosynth Carbosynth^® (Compton, UK).

Staphylococcus epidermidis, S. hominis, and S. haemolyticus isolates (n = 47) demonstrating reduced susceptibility to linezolid were collected in 2014–2018 in six Moscow hospital laboratories and transferred to the central laboratory Pediatric Research and Clinical Centre for Infectious Diseases (PRCCID) together with record forms. Personal data of patients were not included in record forms; ethical approval for the study was not required. Control of CoNS identification was performed in the central laboratory by MALDI-TOF mass spectrometry (Microflex LT, Bruker Daltonics, Germany) following the manufacturer’s instructions. Antimicrobial susceptibilities to 22 antibiotics (Molekula, United Kingdom), including linezolid (Sigma-Aldrich, United States), tedizolid (Bayer, Germany), teicoplanin, oritavancin, telavancin, and dalbavancin (Biosynth Carbosynth, United Kingdom) were tested by broth microdilution in cation-adjusted Mueller–Hinton broth (Bio-Rad, Marnes-la-Coquette, France) and interpreted according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2020) recommendations (Breakpoint tables for interpretation of MICs and zone diameters, Version 10.0, 2020.¹).